Glycosylated haemoglobin (A1c) best values for type 2 diabetes in the battlefield much ado about nothing? (apparently)

Davide Maggi, Fabrizio Montecucco, Gianfranco Adami, Renzo Cordera

Research output: Contribution to journalArticle

Abstract

Despite intensive research, therapy of diabetes mellitus type 2 (T2DM) is far from be effective. The most important unresolved issue is to establish a safe glycosylated hemoglobin C (A1c) value well balanced between benefit and side effects. As a result different guidelines suggest different A1c targets generating confusion for patients and clinicians. Here we report two observations which might support a relaxed A1c as suggested by American college of physician (ACP).

Original languageEnglish
Article number48
JournalDiabetology and Metabolic Syndrome
Volume11
Issue number1
DOIs
Publication statusPublished - Jun 20 2019

Fingerprint

Glycosylated Hemoglobin A
Type 2 Diabetes Mellitus
Guidelines
Physicians
Research
Therapeutics
glycosylated hemoglobin C

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Glycosylated haemoglobin (A1c) best values for type 2 diabetes in the battlefield much ado about nothing? (apparently). / Maggi, Davide; Montecucco, Fabrizio; Adami, Gianfranco; Cordera, Renzo.

In: Diabetology and Metabolic Syndrome, Vol. 11, No. 1, 48, 20.06.2019.

Research output: Contribution to journalArticle

@article{fa415dcbe1ce4a8fb30120b87d86fc0d,
title = "Glycosylated haemoglobin (A1c) best values for type 2 diabetes in the battlefield much ado about nothing? (apparently)",
abstract = "Despite intensive research, therapy of diabetes mellitus type 2 (T2DM) is far from be effective. The most important unresolved issue is to establish a safe glycosylated hemoglobin C (A1c) value well balanced between benefit and side effects. As a result different guidelines suggest different A1c targets generating confusion for patients and clinicians. Here we report two observations which might support a relaxed A1c as suggested by American college of physician (ACP).",
author = "Davide Maggi and Fabrizio Montecucco and Gianfranco Adami and Renzo Cordera",
year = "2019",
month = "6",
day = "20",
doi = "10.1186/s13098-019-0442-x",
language = "English",
volume = "11",
journal = "Diabetology and Metabolic Syndrome",
issn = "1758-5996",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Glycosylated haemoglobin (A1c) best values for type 2 diabetes in the battlefield much ado about nothing? (apparently)

AU - Maggi, Davide

AU - Montecucco, Fabrizio

AU - Adami, Gianfranco

AU - Cordera, Renzo

PY - 2019/6/20

Y1 - 2019/6/20

N2 - Despite intensive research, therapy of diabetes mellitus type 2 (T2DM) is far from be effective. The most important unresolved issue is to establish a safe glycosylated hemoglobin C (A1c) value well balanced between benefit and side effects. As a result different guidelines suggest different A1c targets generating confusion for patients and clinicians. Here we report two observations which might support a relaxed A1c as suggested by American college of physician (ACP).

AB - Despite intensive research, therapy of diabetes mellitus type 2 (T2DM) is far from be effective. The most important unresolved issue is to establish a safe glycosylated hemoglobin C (A1c) value well balanced between benefit and side effects. As a result different guidelines suggest different A1c targets generating confusion for patients and clinicians. Here we report two observations which might support a relaxed A1c as suggested by American college of physician (ACP).

UR - http://www.scopus.com/inward/record.url?scp=85067554742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067554742&partnerID=8YFLogxK

U2 - 10.1186/s13098-019-0442-x

DO - 10.1186/s13098-019-0442-x

M3 - Article

VL - 11

JO - Diabetology and Metabolic Syndrome

JF - Diabetology and Metabolic Syndrome

SN - 1758-5996

IS - 1

M1 - 48

ER -